{"entity":{"id":"nct05009329","kind":"trial","name":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","aka":[],"tldr":"A phase 1/2 trial of Glecirasib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.","summary":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China is a phase 1/2 interventional study registered as NCT05009329 by Allist Pharmaceuticals, Inc., with 315 participants enrolled, started 2021-07-26 and due to reach its primary completion in 2026-08. Interventions recorded: JAB-21822.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05009329","url":"https://clinicaltrials.gov/study/NCT05009329"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","kras-g12c-nsclc"],"sections":[],"technologies":["kinase-inhibitors","kras-inhibitors"],"targets":[],"drugs":["glecirasib"],"companies":["allist"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05009329-nat-med-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05009329","phase":"1/2","setting":"Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation","sponsor":"Allist Pharmaceuticals, Inc.","started":"2021-07-26","startedType":"actual","enrolled":315,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05009329/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/"}],"company":[{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}],"paper":[{"id":"paper-nct05009329-nat-med-2025","kind":"paper","name":"Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial","route":"/key-papers/paper-nct05009329-nat-med-2025/"}]}}